Details of the Drug

General Information of Drug (ID: DM5JWV9)

Drug Name

Tiazofurin

Synonyms

Riboxamide; TCAR; TIZ; Tiazofurina; Tiazofurine; Tiazofurinum; Tiazole; Tiazofurin [USAN]; Tiazofurina [Spanish]; Tiazofurinum [Latin]; Cpd-5825; Tiazofurin (USAN); Tiazofurine (INN); 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; 2-ribofuranosylthiazole-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

ATC Code

L01XX18: Tiazofurin

L01XX: Other antineoplastic agents

L01X: OTHER ANTINEOPLASTIC AGENTS

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

260.269

Logarithm of the Partition Coefficient (xlogp)

-1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 2.4 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 5.9 hours [2]
Unbound Fraction: The unbound fraction of drug in plasma is 0.47% [2]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.1 L/kg [2]

Chemical Identifiers

Formula: C9H12N2O5S
IUPAC Name: 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide
Canonical SMILES: C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
InChI: InChI=1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1
InChIKey: FVRDYQYEVDDKCR-DBRKOABJSA-N

Cross-matching ID

PubChem CID: 457954
ChEBI ID: CHEBI:90239
CAS Number: 60084-10-8
UNII: ULJ82834RE
DrugBank ID: DB13243
TTD ID: D0S7DV
INTEDE ID: DR2129

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)	TTL7C8Q	IMDH1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Nicotinamide riboside kinase 1 (NRK1)	DENV24I	NRK1_HUMAN	Substrate	[4]
Nicotinamide riboside kinase 2 (NRK2)	DE8DJ3N	NRK2_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Gene/Protein Processing	[5]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	De novo synthesis of two new cytotoxic tiazofurin analogues with modified sugar moieties. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3167-70.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
4	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
5	Regulation of the signal transduction program by drugs. Adv Enzyme Regul. 1997;37:35-55. doi: 10.1016/s0065-2571(96)00025-8.